The extent to which sodium-glucose co-transporter-2 (SGLT2) inhibitors increase the risk of genital infections in routine clinical care, compared with other antidiabetic medications, is not clear, or whether the increased risk is consistent across gender or age subgroups, within individual SGLT2 agents, or if it is more pronounced at a particular time after treatment initiation. We conducted a retrospective cohort study using two US commercial claims databases (2013)(2014)(2015)(2016)(2017). In the primary analysis, 1:1 propensity score-matched cohorts of female and male subjects with type 2 diabetes mellitus initiating SGLT2 versus dipeptidyl peptidase-4 inhibitors were created. 
The extent to which sodium-glucose co-transporter-2 (SGLT2) inhibitors increase the risk of genital infections in routine clinical care, compared with other antidiabetic medications, is not clear, or whether the increased risk is consistent across gender or age subgroups, within individual SGLT2 agents, or if it is more pronounced at a particular time after treatment initiation. We conducted a retrospective cohort study using two US commercial claims databases (2013) (2014) (2015) (2016) (2017) . In the primary analysis, 1:1 propensity score-matched cohorts of female and male subjects with type 2 diabetes mellitus initiating SGLT2 versus dipeptidyl peptidase-4 inhibitors were created. The outcome was a composite of genital candidal infections, vaginitis or vulvovaginitis in women, and genital candidal infections, balanitis, balanoposthitis, phimosis or paraphimosis in men. Among propensity scorematched cohorts of 129 994 women and 156 074 men, the adjusted hazard ratio (HR) and excess risk per 1000 person-years for SGLT2 versus DPP-4 inhibitors was 2.81 (95% confidence interval
[CI], 2.64, 2.99) and 87.4 (95% CI, 79.1, 96.2) respectively for women, and was 2.68 (95% CI, 2.31, Table S1 for exclusion criteria definitions). Analysis was stratified by gender to account for the different nature and incidence of genital infections.
| Propensity score matching
To mitigate the potential for confounding, new initiators of SGLT2
inhibitors were matched to new initiators of DPP4 inhibitors according to their estimated propensity score (PS), which modelled the probability of initiating an SGLT2 inhibitor compared with a DDP4 inhibitor on cohort entry, given 44 baseline covariates (Tables S2-S5 in Appendix S1) assessed 6 months prior to drug initiation, which included sociodemographic variables (e.g. age, sex), diabetes severity and diabetic drug use (e.g. complications of diabetes, insulin use), common comorbid conditions (e.g. hypertension, ischaemic heart disease), and conditions related to risk of genital infections (for example, oestrogen use, history of urinary tract infections). We PS-matched an SGLT2 initiator with a DPP4 initiator within a maximum caliper of 0.01.
| Follow-up and study endpoints
Patients were censored on the earliest of the following events: end of healthcare or pharmacy continuous eligibility, switching exposure class or adding therapy from the comparator class, therapy discontinuation (defined as a 30-day treatment gap after the expiration of the last prescription's supply), 365 days, or the last date of data availability.
The primary outcome was an episode of genital infections, which was defined as a composite of genital candidal infections, vaginitis or vulvovaginitis for women, and genital candidal infections, balanitis, balanoposthitis, phimosis or paraphimosis for men (see Table S1 in Appendix S1
for outcome definitions). As a secondary outcome, we restricted the definition of genital infections to those related to candidal infections only.
| Statistical analysis
We assessed the performance of the PS by cross-tabulating the baseline covariates by exposure group before and after matching.
HbA1c, which was available for 10% of the pooled population, was not included in the PS but was used to assess the glycaemic control before and after matching. In the PS-matched cohort, we estimated the risk of genital infections for SGLT2 inhibitors compared with DPP4 inhibitors by calculating the number of events, incidence rates, and hazard ratios with 95% confidence intervals (CI). The adjusted excess risk for genital infections was estimated by I 0 x (HR-1) where I 0 is the crude rate of the outcome in the control group per 1000 person-years, and HR is the adjusted hazard ratio (95% CI were calculated analogously). All statistical analyses were performed with the use of the validated Aetion platform (see the Supporting Information Appendix S1). 18 Analyses were performed within each database and estimates were pooled through fixedeffects meta-analysis (see the Supporting Information Appendix S1
for further information).
| Sensitivity and secondary analysis
To assess the robustness of our analysis, we created a new cohort of patients, changing the active comparator from DPP4 inhibitors to glucagon-like peptide-1 (GLP1) receptor agonists. We also conducted two subgroup analyses. First, because older patients may have a higher risk of SGLT2-induced infections, we examined a subgroup of patients >60 years. Second, we ran stratified analyses comparing dapagliflozin and empagliflozin to canagliflozin (the most commonly utilized agent during the study period in the United States). Within all subgroups, the PS was re-estimated, and patients were re-matched based on the newly estimated PS.
| RESULTS
Within the two databases, there were 174 812 patients that initiated an SGLT2 inhibitor and 336 922 patients that initiated a DPP4 inhibitor (Table 1) . Prior to matching, and for both genders, the two groups differed in several baseline covariates. Compared with their SGLT2-inhibitor counterparts, DPP4-inhibitor initiators were older, less likely to have used insulin or GLP1 receptor agonists during the baseline, and more likely to have a history of urinary tract infections.
Within the PS-matched cohort-comprising 286 068 patients in total-the baseline covariates (including HbA1c, which was not included in the PS model) were comparable with no standardized differences exceeding 10% (see Tables S2-S5 for baseline characteristics prior and post-PS-matching by gender and database).
| Primary analysis
Prior to adjustment, the HR for genital infections among women and men was 3.38 (95% CI, 3.22-3.55) and 2.78 (95% CI, 2.50-3.10; see Table S6 for pooled and database-specific estimates). Table 2 reports pooled PS-matched estimates (see Table S7 for database-specific estimates Figure S1 shows the pooled 1:1 PS-matched Kaplan-Meier curves describing the cumulative incidence of genital infections among men and women; the increase in risk was apparent within the first month of SGLT2 inhibitor initiation and remained elevated throughout the course of therapy.
| Sensitivity and secondary analysis
Changing the active comparator from DPP4 inhibitor to GLP1 
| DISCUSSION
In a large population-based study, we found that SGLT2 inhibitor use was associated with an approximately 3-fold increase in the risk of genital infections compared with other diabetes treatment. This Tables S3-S6 for baseline characteristics by gender and database prior to and post-PS-matching. b Standardized difference > 10%, prematched cohort; women. c Standardized difference > 10%, prematched cohort; men. d HbA1c (available for 10% of the pooled population; not included in the PS) was utilized to assess the presence of adequate therapeutic equipoise between the SGLT2 and their non-gliflozin counterparts prior to PS-matching and to assess potential residual confounding after PS-matching; mean (SD) are shown. e Oestrogen use defined as oral contraceptives containing oestrogen and hormone replacement therapy. association was consistent across genders and databases, robust to change of active comparator, and larger in magnitude in the subgroup of patients aged ≥60 years. Within individual SGLT2 inhibitors, the risk appeared similar across agents, and remained elevated throughout the duration of therapy.
Our primary findings are consistent with previous RCTs that found a 3-to 5-fold increase in the risk of genital infections. 2, 8, 9 However, previous clinical trials on SGLT2 inhibitors neither evaluated the incidence of genital infections by age or sex, nor performed direct comparisons across individual SGLT2 inhibitors or examined duration of therapy. A network meta-analysis that indirectly compared the risk of genital infections among individual SGLT2 inhibitors found canagliflozin had a slightly higher risk of genital infections, followed by dapagliflozin and empagliflozin. 6 However, although we utilized PS-matching to mitigate concern over bias by characteristics associated with SGLT2 inhibitor use and genital infections, some potential confounders were not available in our data (for example, circumcision status or behavioural risk factors) 19 ; however, given the magnitude of the effect size, this association is unlikely to be fully explained by the presence of residual confounding. Second, by requiring a medical encounter related to genital infections, we may have systematically excluded cases of genital infections with a milder underlying symptomatology. However, the choice of a more specific outcome definition maximizes study validity. Third, our findings are generalizable to commercially insured patients. However, it is unlikely that the risk of genital infections would vary among patients with different insurance types. Fourth, because this was a claim-based study, the analysis did not control for some important variables such as duration of diabetes or body mass index; however, claims-based proxies have been shown to be good surrogates for these characteristics. 20 The use of SGLT2 inhibitors was associated with an approxi- 
